These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19088154)

  • 1. Overview of gefitinib in non-small cell lung cancer: an Asian perspective.
    Jiang H
    Jpn J Clin Oncol; 2009 Mar; 39(3):137-50. PubMed ID: 19088154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
    Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
    Togashi Y; Hayashi H; Nakagawa K; Nishio K
    Drug Des Devel Ther; 2014; 8():1037-46. PubMed ID: 25114510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
    Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
    Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.
    Chang A; Parikh P; Thongprasert S; Tan EH; Perng RP; Ganzon D; Yang CH; Tsao CJ; Watkins C; Botwood N; Thatcher N
    J Thorac Oncol; 2006 Oct; 1(8):847-55. PubMed ID: 17409969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of gefitinib in the management of Asian patients with non-small cell lung cancer.
    Chang AY
    Expert Opin Investig Drugs; 2008 Mar; 17(3):401-11. PubMed ID: 18321238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.
    Sanford M; Scott LJ
    Drugs; 2009 Nov; 69(16):2303-28. PubMed ID: 19852530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
    Park K; Goto K
    Curr Med Res Opin; 2006 Mar; 22(3):561-73. PubMed ID: 16574039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib in non small cell lung cancer.
    Costanzo R; Piccirillo MC; Sandomenico C; Carillio G; Montanino A; Daniele G; Giordano P; Bryce J; De Feo G; Di Maio M; Rocco G; Normanno N; Perrone F; Morabito A
    J Biomed Biotechnol; 2011; 2011():815269. PubMed ID: 21660144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
    Yang CH
    Lung Cancer; 2008 Jun; 60 Suppl 2():S23-30. PubMed ID: 18513581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
    Costa DB; Kobayashi S; Tenen DG; Huberman MS
    Lung Cancer; 2007 Oct; 58(1):95-103. PubMed ID: 17610986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
    Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
    Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
    Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib therapy for non-small cell lung cancer.
    Birnbaum A; Ready N
    Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.
    Yang JC; Kang JH; Mok T; Ahn MJ; Srimuninnimit V; Lin CC; Kim DW; Tsai CM; Barraclough H; Altug S; Orlando M; Park K
    Eur J Cancer; 2014 Sep; 50(13):2219-30. PubMed ID: 24953333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.